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Introduction: This phase 2 randomized study evaluated trebananib (AMG 386), a peptide-Fc fusion
protein that inhibits angiogenesis by neutralizing the interaction of angiopoietin-1 and -2 with Tie2, in
combination with paclitaxel with or without bevacizumab in previously untreated patients with HER2-
negative locally recurrent/metastatic breast cancer.
Methods: Patients received paclitaxel 90 mg/m2 once weekly (3-weeks-on/1-week-off) and were
randomly assigned 1:1:1:1 to also receive blinded bevacizumab 10 mg/kg once every 2 weeks plus either
trebananib 10 mg/kg once weekly (Arm A) or 3 mg/kg once weekly (Arm B), or placebo (Arm C); or open-
label trebananib 10 mg/kg once a week (Arm D). Progression-free survival was the primary endpoint.
Results: In total, 228 patients were randomized. Median estimated progression-free survival for Arms A,
B, C, and D was 11.3, 9.2, 12.2, and 10 months, respectively. Hazard ratios (95% CI) for Arms A, B, and D
versus Arm C were 0.98 (0.61e1.59), 1.12 (0.70e1.80), and 1.28 (0.79e2.09), respectively. The objective
response rate was 71% in Arm A, 51% in Arm B, 60% in Arm C, and 46% in Arm D. The incidence of grade 3/
4/5 adverse events was 71/9/4%, 61/14/5%, 62/16/3%, and 52/4/7% in Arms A/B/C/D. In Arm D, median
progression-free survival was 12.8 and 7.4 months for those with high and low trebananib exposure
(AUCss  8.4 versus < 8.4 mg$h/mL), respectively.cology, Institut Curie, 26 rue d'Ulm, Paris 75005, France. Tel.: þ33 144324675; fax: þ33 144324671.
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10.1016/j.breast.2014.11.003Conclusions: There was no apparent prolongation of estimated progression-free survival with the
addition of trebananib to paclitaxel and bevacizumab at the doses tested. Toxicity was manageable.
Exposure-response analyses support evaluation of combinations incorporating trebananib at
doses > 10 mg/kg in this setting.
Trial Registration: ClinicalTrials.gov, NCT00511459
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Two receptor tyrosine kinase pathways important in induction
and regulation of tumor angiogenesis are the vascular endothelial
growth factor (VEGF) and angiopoietin axes [1,2]. Angiopoietin-1
and -2 inﬂuence the vasculature by binding to the Tie2 receptor
[2]. Although the VEGF and angiopoietin pathways are distinct, they
interact [2] and simultaneous blockade of both pathways may
improve inhibition of tumor growth compared with blocking either
pathway alone [3e5].
Several studies have assessed bevacizumab (an anti-VEGF-A
antibody) plus chemotherapy as ﬁrst-line treatment for recurrent
or metastatic HER2-negative breast cancer [6e9]. In the E2100
study, bevacizumab plus paclitaxel versus paclitaxel alone signiﬁ-
cantly improved progression-free survival (PFS; 11.8 versus 5.9
months, respectively; P < 0.001) and objective response rate (ORR;
36.9% versus 21.2%; P < 0.001) in the ﬁrst-line setting [8]. However,
there was no signiﬁcant difference in overall survival (OS) between
the two treatment groups (26.7 versus 25.2 months; P ¼ 0.16).
Improvements in PFS have also been reported for combinations of
bevacizumab with other chemotherapy regimens as ﬁrst-line
therapy for metastatic disease [6,7,9]. Given these improvements
in PFS, but lack of concomitant improvement in OS, there has been
considerable recent debate regarding the role of bevacizumab in
the treatment of metastatic breast cancer [10e12].
Trebananib is an investigational, intravenously administered
peptide-Fc fusion protein that binds to and inhibits the interaction
of angiopoietin-1 and -2 with the Tie2 receptor. Tumor xenograft
studies with trebananib have shown that dual inhibition of
angiopoietin-1 and -2 in the context of concurrent VEGF blockade
results in signiﬁcantly better efﬁcacy than inhibiting either
target alone [1,13]. In phase 1 monotherapy and chemotherapy
combination studies in patients with solid tumors, trebananib
demonstrated antitumor activity and a speciﬁc toxicity proﬁle
[14,15]. In a randomized, placebo-controlled phase 2 study of
trebananib plus weekly paclitaxel, patients with recurrent ovarian
cancer who received trebananib demonstrated prolonged esti-
mated PFS compared with those who received placebo with evi-
dence of doseeresponse and exposure-response effects [16,17].
Treatment was tolerable, with speciﬁc and manageable toxicities.
The objectives of this study were to estimate the treatment effect of
trebananib (as assessed by PFS) when administered in combination
with paclitaxel with or without bevacizumab in ﬁrst-line treatment
of locally advanced or metastatic HER2-negative breast cancer.
Methods
Patients
Eligible women (18 years) had histologically or cytologically
conﬁrmed HER2-negative (expression  2þ by immunohisto-
chemistry and/or negative by ﬂuorescence in situ hybridization)
adenocarcinoma of the breast with locally recurrent (not amenable
to resection with curative intent) or metastatic disease for which
they had not been previously treated. Additionally, patients had, et al., Trebananib (AMG 38
t or metastatic breast cancerEastern Cooperative Oncology Group (ECOG) status  1; measur-
able/nonmeasurable disease per modiﬁed Response Evaluation
Criteria in Solid Tumors (RECIST) version 1.0 [18], complete
computed tomography (CT) or magnetic resonance imaging (MRI)
scans and whole-body bone scintigraphy  28 days before
randomization; and adequate hematologic, renal, hepatic, and
cardiac function. Key exclusion criteria were inﬂammatory breast
cancer; central nervous system metastasis; adjuvant/neoadjuvant
taxane treatment within 1 year; prior radiation therapy, radio-
frequency ablation, percutaneous cryotherapy, or hepatic
chemoembolization  14 days before randomization; grade > 1
peripheral neuropathy; uncontrolled hypertension; history of
arterial or venous thrombosis within 1 year; bleeding diathesis
within 6 months; and previous treatment with VEGF or angio-
poietin axis inhibitors. Patients providedwritten informed consent;
study procedures were approved by an independent ethics com-
mittee/institutional review board at each center.
Study design and treatment
This was a randomized, placebo-controlled, 4-arm, multicenter
(70 sites in four countries), phase 2 estimation study. Patients
received intravenous (IV) paclitaxel 90 mg/m2 onceweekly (QW; 3-
weeks-on/1-week-off) and were randomly assigned 1:1:1:1 to
receive trebananib 10 mg/kg QW plus bevacizumab 10 mg/kg IV
every 2 weeks (Q2W; Arm A), trebananib 3 mg/kg QW plus bev-
acizumab 10 mg/kg IV Q2W (Arm B), placebo plus bevacizumab
10 mg/kg IV Q2W (Arm C), or trebananib 10 mg/kg QW (Arm D).
The doses of trebananib used in this study were selected based on
pharmacokinetic analysis from the ﬁrst-in-human monotherapy
study. A maximum-tolerated dose was not reached in that study
but doses greater than 3 mg/kg QW provided trough concentra-
tions that were above the optimal biologic dose for tumor xenograft
growth inhibition [1,14]. Treatment in Arms A, B, and C was double-
blind; treatment in Arm D was open-label. Randomization was
stratiﬁed by adjuvant taxane exposure (yes/no) and number of
metastatic sites (3/>3). Treatment continued until disease pro-
gression, unacceptable toxicity, or withdrawal of consent. Doses of
trebananib, bevacizumab or paclitaxel could be withheld according
to protocol-speciﬁed rules. Doses of paclitaxel could be reduced to
65 mg/m2 in the event of toxicity; dose modiﬁcations for
trebananib and bevacizumab were not permitted.
The primary endpoint was PFS, deﬁned as the time from
randomization to disease progression (per RECIST) as assessed by
investigators, or death. Secondary endpoints included ORR
(conﬁrmed complete response þ partial response), duration of
response (DOR), OS, time to response, incidence of adverse events
(AEs), anti-trebananib antibody formation, and pharmacokinetics
of trebananib.
Efﬁcacy assessments
CT/MRI were performed at baseline and every 8 ± 1 weeks
thereafter. Tumor response was assessed according to RECIST
version 1.0 [18]. Patients who discontinued treatment without6) plus weekly paclitaxel with or without bevacizumab as ﬁrst-line
: A phase 2 randomized study, The Breast (2014), http://dx.doi.org/
Fig. 1. Disposition of patients in the study. B ¼ bevacizumab; P ¼ paclitaxel. *Includes determination of ineligibility and lost to follow-up.
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every 8 ± 1 weeks until disease progression or initiation of new
treatment. Long-term follow-up continued for 48months (from the
date the last patient was randomized).
Adverse events and immunogenicity
AEs occurring from study day 1e37 days after the last dose of
study medication were classiﬁed according to the National Cancer
Institute Common Terminology Criteria for Adverse Events (NCI-Table 1
Baseline demographics and clinical characteristics.
Arm A
Trebananib 10 mg/kg QW þ
Paclitaxel þ Bevacizumab
n ¼ 56
A
T
P
n
Race/ethnicity, %
White 80 9
Asian 13 4
Black 2 0
Hispanic 4 0
Other 2 0
Median (range) age, y 56.5 (32e75) 5
ECOG performance status, %
0 61 6
1 38 3
2 2a 0
Median (range) time since primary diagnosis, mo 50.3 (1e152) 3
Stage IV disease at initial diagnosis, % 18 2
Metastatic sites, %
3 79 7
>3 21 2
Sites of disease, %
Liver 43 5
Lung 39 4
Bone 63 6
Estrogen receptor/progesterone receptor status, %
Positive 80 8
Negative 18 1
Unknown 2 0
HER2/neuenegative disease status, % 98a 1
Triple-negative status, %b 16 1
Unknown 4 0
Adjuvant taxane treatment, % 18 2
a Protocol violation (one patient was HER2/neuepositive).
b Deﬁned as negative for estrogen receptor, progesterone receptor, and HER2/neu (no
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10.1016/j.breast.2014.11.003CTCAE), version 3.0. Serum samples were collected predose on day
1 of cycles 1 to 3, day 15 of cycle 6, and every 16 weeks thereafter
for the measurement of anti-trebananib binding and neutralizing
antibodies as previously described [14].
Pharmacokinetic and exposure-response analyses
Serum samples were collected postinfusion at weeks 1, 5, and 15
to assess the maximum observed concentration (Cmax) and pre-
infusion at weeks 1, 3, 5, 9, 15, and every 8 weeks thereafter torm B
rebananib 3 mg/kg QW þ
aclitaxel þ Bevacizumab
¼ 57
Arm C
Placebo þ Paclitaxel þ
Bevacizumab
n ¼ 58
Arm D
Trebananib 10 mg/kg QW
(Open-Label) þ Paclitaxel
n ¼ 57
6 83 91
10 7
3 2
2 0
2 0
6 (26e83) 51.5 (31e74) 52 (27e76)
7 60 70
3 40 30
0 0
5.9 (0e242) 47.4 (0e300) 40.4 (0e180)
3 21 21
7 79 72
3 21 28
4 45 44
2 31 42
3 62 54
2 78 65
8 21 33
2 2
00 100 100
8 21 32
2 4
1 19 16
ampliﬁcation by FISH/CISH or 0/1 þ by immunochemistry).
6) plus weekly paclitaxel with or without bevacizumab as ﬁrst-line
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trebananib concentrations were measured as previously described
[14]. In pharmacokinetic/pharmacodynamic analyses, Cox regres-
sion models were used to evaluate the effect of the area under the
concentrationeversusetime curve at steady state (AUCss) on PFS
[16]. The cut-point for trebananib high versus low exposure (AUCss)
in patients who received blinded trebananib (Arms A or B) was
based on the median AUCss in Arm A; the cut-point in the open-
label treatment arm (Arm D) represented median AUCss in that
group.
Statistical analysis
A study size of 220 patients (n ¼ 55/arm) was planned.
Assuming median PFS of 11 months in Arm C and 16.9 months in
Arms A and B combined (54% relative increase), the target event
goal of 110 PFS events (68 in Arms A/B combined and 42 in Arm C),
would allow estimation of the PFS hazard ratio (HR) for Arms A andFig. 2. Progression-free survival. KaplaneMeier plot of progression-free s
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10.1016/j.breast.2014.11.003B relative to Arm C with a two-sided conﬁdence interval  0.34,
assuming an observed HR of 0.65. The primary analysis was con-
ducted using the all-randomized analysis set. Patients were
analyzed according to treatment randomization, regardless of
treatment received (intent to treat). Analyses of ORR, DOR, time to
response, and reduction in tumor burden included patients with
1 unidimensionally measurable lesion at baseline. Safety analyses
were conducted for all randomized patients who received 1 dose
of trebananib, bevacizumab, or paclitaxel analyzed according to
treatment received.
For analyses of PFS, a Cox regression model stratiﬁed by the
randomization strata was used to estimate the HR and corre-
sponding CIs for Arms A, B, and D individually, and for Arms A and B
combined, versus Arm C [19]. Log-rank tests stratiﬁed by the
randomization factors were used to evaluate differences in PFS for
each comparison; P values were descriptive. KaplaneMeier me-
dians and two-sided 95% CIs were derived for time-to-event ana-
lyses [20]. Tarone's test, stratiﬁed by the randomization factors, wasurvival among patients in (A) Arms A, B, and C and (B) Arms C and D.
6) plus weekly paclitaxel with or without bevacizumab as ﬁrst-line
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treatment arm, and for Arms A/B combined, exact binomial two-
sided 95% CIs were generated for ORR. Wilson's score method
with continuity correction was used to calculate 95% CIs for
between-arm differences in ORR. Efﬁcacy analyses were not
adjusted for multiple comparisons.
Results
Patients
Two hundred and twenty eight patients were randomized
(Fig. 1). Demographics and baseline characteristics were generally
well balanced among treatment arms (Table 1). However, the per-
centage of patients with >3 sites of metastatic disease or triple-
negative status was higher in Arm D than in other arms. Median
time from primary diagnosis was 50.3, 35.9, 47.4, and 40.4 months
for Arms A, B, C, and D, respectively. The median number of
administered trebananib/placebo cycles was 9, 6, 9 and 8 in Arms A,
B, C and D, respectively; the median number of administered
bevacizumab cycles was 9, 6 and 8.5 in Arms A, B and C, respec-
tively. In each arm, patients received a median of 6 cycles of
paclitaxel with a mean (SD) relative dose intensity of 0.8 (0.1).
Median (range) follow-up time for all patients was 66.4 (1e124)
weeks.
Progression-free survival
Median PFS was 11.3, 9.2, 12.2, and 10.0 months in Arms A, B, C,
and D, respectively (Fig. 2). Pairwise comparisons of each arm
versus Arm C yielded an HR of 0.98 (95% CI, 0.61e1.59; P¼ 0.95) for
Arm A, 1.12 (0.70e1.80; P ¼ 0.64) for Arm B, and 1.28 (95% CI,
0.79e2.09; P ¼ 0.31) for Arm D. The HR for Arms A and B combined
versus Arm C was 1.05 (95% CI, 0.70e1.57; P ¼ 0.83). There was no
evidence of a doseeresponse effect. In an ad hoc analysis, median
estimated PFS was shorter among triple-negative patients in all
four treatment arms compared with patients positive for 1 re-
ceptor (Arm A, 7.4 versus 12.0 months; Arm B, 5.3 versus 12.7
months; Arm C, 8.4 versus 12.6 months; Arm D, 7.3 versus 11.1Table 2
Efﬁcacy.
Arm A
Trebananib 10 mg/kg QW þ
Paclitaxel þ Bevacizumab
n ¼ 56
A
T
P
n
Progression-free survival (PFS)a
Patients with events, % 64 6
Median (95% CI) KaplaneMeier PFS time, mo 11.3 (10.7e14.4) 9
Cox regression model
PFS vs Arm C, HR (95% CI) 0.98 (0.61e1.59) 1
P 0.946 0
PFS Arms A þ B vs Arm C, HR (95% CI) 1.05 (0.70e1.57)
P 0.830
Tarone test, P 0.580
Conﬁrmed objective response
Patients with measurable disease at baseline, n (%) 41 (73) 4
Best conﬁrmed response, %
Complete response 7 2
Partial response 63 4
Stable disease 24 2
Progressive disease 2 1
Unevaluablea 2 6
Not done 0 6
Conﬁrmed objective response rate,
% (95% CI)
71 (55e84) 5
Median (range) time to response, weeks 8.0 (7.0e48.0) 8
Median (95% CI) duration of response, weeks 41.6 (24.0e55.0) 4
a Includes patients with an assessment of complete response, partial response, or stab
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are not reported.
Objective response rate
Most patients had measurable disease at baseline (Table 2).
Conﬁrmed ORRs in Arms A, B, C, and Dwere 71%, 51%, 60%, and 46%,
respectively. Median time to response was longer and duration of
response was shorter in Arm D than in the other three arms
(Table 2).
Pharmacokinetic/pharmacodynamic analyses
The pharmacokinetics of trebananib were dose proportional
when administered in combination with bevacizumab and/or
paclitaxel and consistent with those reported previously [14]. At
steady state, median trebananib Cmax (week 5) was 260, 79.0, and
270 mg/mL in Arms A, B and D, respectively. Median trebananib Cmin
at steady state (weeks 5, 9, 15, and thereafter) ranged from
13.5e15.2, 3.36e4.20 and 13.8e18.0 mg/mL in Arms A, B, and D,
respectively.
An exploratory analysis investigated the relationship between
trebananib exposure and response. Patients in Arm A or B who had
AUCss  9.1 mg$h/mL (high exposure; n ¼ 29) had a median PFS of
14.5months (HR versus placebo, 0.72 [95% CI, 0.40e1.30]; P¼ 0.28);
those with AUCss < 9.1 mg$h/mL (low exposure; n ¼ 83) had a
median PFS of 9.6 months (HR versus placebo, 1.22 [95% CI,
0.80e1.85]; P ¼ 0.36; Fig. 3A). In Arm D, median PFS in the high
(AUCss  8.4 mg$h/mL, n ¼ 28) and low (AUCss < 8.4 mg$h/mL,
n ¼ 28) exposure groups was 12.8 and 7.4 months, respectively (HR
high versus low, 0.67 [95% CI, 0.32e1.37]; P ¼ 0.27; Fig. 3B). In the
blinded arms, ORR in the high-exposure group was 95% compared
with 51% in the low-exposure group.
Adverse events
Incidence of grade  3 AEs was similar in Arms A (84%), B (81%),
and C (81%) but was lower (63%) in Arm D (Table 3). In the four
treatment arms (A, B, C, and D), 27%, 40%, 36%, and 30% of patients,rm B
rebananib 3 mg/kg QW þ
aclitaxel þ Bevacizumab
¼ 57
Arm C
Placebo þ Paclitaxel þ
Bevacizumab
n ¼ 58
Arm D
Trebananib 10 mg/kg QW
(Open-Label) þ Paclitaxel
n ¼ 57
7 64 56
.2 (6.9e13.8) 12.2 (8.5e13.0) 10.0 (7.3e14.5)
.12 (0.70e1.80) 1.28 (0.79e2.09)
.642 0.314
9 (86) 42 (72) 46 (81)
0 4
9 60 41
7 31 30
0 5 13
0 2
5 9
1 (36e66) 60 (43e74) 46 (31e61)
.1 (7.0e34.6) 8.7 (7.0e55.7) 15.3 (6.9e32.0)
8.0 (24.0e64.9) 39.0 (29.1e47.9) 32.0 (23.7e56.0)
le disease before the ﬁrst scheduled assessment with no additional assessment.
6) plus weekly paclitaxel with or without bevacizumab as ﬁrst-line
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pyrexia); 73%, 67%, 67%, and 43% had grade 3 AEs deemed related
to any of the administered study treatments; and 16%, 23%,16%, and
4% had AEs leading to permanent treatment or study discontinu-
ation. Overall, there were no apparent dose-related trends in the
incidence of AEs. Most of the deaths that occurred on study (Arm A,
n¼ 17, Arm B, n¼ 21; Arm C, n¼ 14; ArmD, n¼ 12) were attributed
to disease progression. Two patients had fatal AEs that were
considered by the investigators to be possibly related to
trebananib/bevacizumab (hemoptysis in Arm B) or paclitaxel
(diarrhea and respiratory failure in Arm B).
Among AEs of interest, edema (Table 4) and speciﬁcally pe-
ripheral edema (Table 3) occurred more frequently in Arms A, B,
and D than in Arm C, with few incidences of grade 3 events (no
grade 4 or 5 events occurred). Hypertension and hemorrhagic
events were reported more often in Arms A, B, and C than in Arm D.
There was one incidence of grade 4 rectal hemorrhage and one of
grade 5 hemoptysis in Arm B. Other noteworthy AEs included oneFig. 3. Relationship between trebananib exposure and progression-free survival. Kaplan
Arm D stratiﬁed by trebananib AUCss.
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10.1016/j.breast.2014.11.003arterial thromboembolic event (grade 4 myocardial infarction in
Arm C), one gastrointestinal perforation (grade 3, Arm B), and one
perirectal abscess (grade 2, Arm C). In some treatment arms, ascites,
pleural effusion, and/or blurred vision occurred (all were grade 1 or
2 with the exception of one grade 3 pleural effusion in Arm B).
These AEs have recently been identiﬁed as speciﬁc risks associated
with trebananib treatment.
Overall, 220 patients had postbaseline immunoassay samples. In
the trebananib treatment arms combined, 13/156 patients devel-
oped anti-trebananib binding antibodies; these were transient in
all but three patients. No trebananib neutralizing antibodies were
detected.
Discussion
In this phase 2 randomized study in patients with HER2-
negative recurrent or metastatic breast cancer, we evaluated the
estimated treatment effect on PFS of paclitaxel plus bevacizumabeMeier plots of progression-free survival among patients in (A) Arms A and B and (B)
6) plus weekly paclitaxel with or without bevacizumab as ﬁrst-line
: A phase 2 randomized study, The Breast (2014), http://dx.doi.org/
Table 3
Incidence of adverse events.
Arm A
Trebananib 10 mg/kg QW þ
Paclitaxel þ Bevacizumab
n ¼ 55
Arm B
Trebananib 3 mg/kg QW þ
Paclitaxel þ Bevacizumab
n ¼ 57
Arm C
Placebo þ Paclitaxel þ
Bevacizumab
n ¼ 58
Arm D
Trebananib 10 mg/kg QW
(Open-Label) þ Paclitaxel
n ¼ 56
Patients with any adverse event, % 100 100 100 100
Grade 3 71 61 62 52
Grade 4 9 14 16 4
Grade 5 4 5 3 7
Adverse events (all grades) occurring in
30% of patients in 1 treatment arm, %
Alopecia 64 61 60 55
Nausea 62 42 45 46
Epistaxis 44 61 50 18
Fatigue 49 58 38 27
Diarrhea 49 56 62 32
Peripheral edema 36 46 19 55
Headache 25 42 47 29
Constipation 24 42 36 23
Hypertension 40 39 38 13
Neutropenia 35 39 41 32
Peripheral neuropathy 35 39 28 38
Arthralgia 27 39 28 23
Vomiting 35 37 29 20
Nail disorder 36 35 24 9
Asthenia 31 33 33 39
Cough 31 26 34 32
Dysgeusia 31 18 31 16
Dysphonia 20 14 33 5
Grade  3 adverse events occurring in
5% of patients in 1 treatment arm, %
Hypertension 18 23 19 4
Neutropenia 18 19 28 18
Peripheral neuropathy 20 7 10 11
Fatigue 5 9 2 2
Peripheral sensory neuropathy 5 7 2 4
Asthenia 7 4 5 5
Diarrhea 4 7 3 0
Alopeciaa 4 7 0 5
Deep vein thrombosis 5 2 0 0
Nausea 2 5 2 2
Vomiting 2 5 2 0
Peripheral edema 2 4 2 5
Back pain 0 5 3 0
Aspartate aminotransferase increased 0 5 2 0
Leukopenia 2 2 3 5
Syncope 2 2 0 5
a Incorrectly reported as grade  3 by investigators.
V. Dieras et al. / The Breast xxx (2014) 1e9 7with or without trebananib and also evaluated PFS among patients
receiving trebananib plus paclitaxel. There was little evidence of
improvement in estimated PFS or ORR among patients receiving
blinded trebananib in combination with bevacizumab at the doses
tested compared with blinded placebo plus bevacizumab. The
estimated median PFS of 10.0 months and ORR of 46% in the open-
label trebananib plus paclitaxel armwere not better thanwhat was
observed with placebo plus bevacizumab and paclitaxel treatment.
Median PFS for patients in the placebo arm was consistent with
median PFS reported for patients receiving bevacizumab plus
paclitaxel in other randomized studies (range, 8.8e12.9 months)
[8,21,22]. ORR among patients in Arms A (71%), B (51%), and C (60%)
was higher than previously reported for bevacizumab plus pacli-
taxel (range, 32%e52%) [8,21e23]. There were some imbalances in
baseline disease characteristics (including the proportion of pa-
tients who had triple-negative status for which the analyses of
efﬁcacy were not adjusted).
Pharmacokinetic/pharmacodynamic analyses of patients with
higher exposure to trebananib support further evaluation of
trebananib at doses > 10 mg/kg in metastatic breast cancer. In
Arm A, median PFS was longer among patients with
AUCss  9.1 mg$h/mL, and in Arm D median PFS was longer amongPlease cite this article in press as: Dieras V, et al., Trebananib (AMG 38
therapy for HER2-negative locally recurrent or metastatic breast cancer
10.1016/j.breast.2014.11.003patients with AUCss  8.4 mg$h/mL. ORR was also improved
among patients in Arms A and B who had high trebananib expo-
sure (with a remarkable ORR of 95%), but there was no evidence
that trebananib exposure inﬂuenced ORR in Arm D. Data from
these exposure-response analyses must be interpreted cautiously
given outcomes among patients in Arms A and B with high tre-
bananib exposure were unadjusted for confounding factors and
only moderately improved compared with patients in the placebo
arm, and the lack of a control group for Arm D. Furthermore, data
from this small estimation study did not demonstrate a
doseeresponse for efﬁcacy in the blinded treatment arms, and the
exposure-response results from the blinded arms should be
interpreted in that context. Of note, exposure-response analysis of
a phase 2 study in patients with recurrent ovarian cancer pro-
duced a similar ﬁnding and supported use of trebananib at 15 mg/
kg QW plus weekly paclitaxel in phase 3 studies [16]. In the phase
3 TRINOVA-1 study, treatment with trebananib 15 mg/kg QW plus
weekly paclitaxel resulted in a signiﬁcant improvement in PFS
compared with placebo plus paclitaxel (HR, 0.66, 95% CI,
0.57e0.77, P < 0.0001) [24]. Trebananib is being investigated at
doses up to 30 mg/kg in combination with chemotherapy and
HER2-inhibitors in a phase 1b study in patients with HER2-6) plus weekly paclitaxel with or without bevacizumab as ﬁrst-line
: A phase 2 randomized study, The Breast (2014), http://dx.doi.org/
Table 4
Incidence of adverse events of special interest.
Arm A
Trebananib 10 mg/kg
QW þ Paclitaxel þ
Bevacizumab
n ¼ 56
Arm B
Trebananib 3 mg/kg QW þ
Paclitaxel þ Bevacizumab
n ¼ 57
Arm C
Placebo þ Paclitaxel þ
Bevacizumab
n ¼ 58
Arm D
Trebananib 10 mg/kg QW
(Open-label) þ Paclitaxel
n ¼ 57
Adverse events of interest, %
Edema 56 60 29 70
Grade  3 2 4 3 7
GI perforation/abscess 0 2a 2b 0
Hemorrhagic events 51 68 55 23
Grade  3 0 4 2 0
Hypokalemia 2 5 7 2
Grade  3 0 4 0 0
Impaired wound healing 2 0 3 0
Grade  3 0 0 2 0
Infusion reactionsc 11 9 10 2
Proteinuriad 4 4 2 4
Pulmonary embolism 0 2 2 0
Grade  3 0 2 2 0
Venous thromboembolic events 7 9 3 2
Grade  3 5 5 3 2
Ascitesc 4 2 3 0
Pleural effusion 5 7 0 9
Grade 3 0 2 0 0
Blurred visionc 7 4 3 0
a Grade 3 gastroinestinal perforation.
b Grade 2 perirectal abscess.
c No grade  3.
d No grade  3; assessed as an adverse event.
V. Dieras et al. / The Breast xxx (2014) 1e98positive locally recurrent/metastatic breast cancer (ClinicalTrials.
gov, NCT00807859).
Although there are some known overlapping toxicities among
the three agents administered, there was little evidence that any of
the combinations resulted in a toxicity proﬁle worse than that
described for these agents in monotherapy or in combination with
chemotherapy. Peripheral edema occurred more frequently among
patients receiving trebananib, consistent with previous studies of
trebananib both alone [14], and combined with chemotherapy
[15,17,24]. In contrast with a previous phase 2 ovarian cancer study
[17], the incidence of hypokalemia was not increased among pa-
tients receiving trebananib. In general, the incidence of AEs asso-
ciated with VEGF pathway inhibitors [25], including hemorrhage,
proteinuria, and hypertension, was similar in Arms A, B, and C, and
the incidence of grade  3 events appeared consistent with those
reported for patients receiving bevacizumab plus paclitaxel in the
E2100 study [8]. Notably, hemorrhagic events and hypertension
occurred more frequently among patients who received blinded
bevacizumab with or without trebananib (ie, those in Arms A, B,
and C) compared with those who received open-label trebananib
(ie, those in Arm D). These results suggest that trebananib did not
increase the incidence of these AEs. There were more venous
thromboembolic events in Arms A and B (7% and 9%, respectively)
than in Arm C (3%); however, these numbers are small and few
patients had grade  3 events. Three other speciﬁc AEs of interest,
recently associated with trebananib treatment, are worth
mentioning: ascites and pleural effusion [24,26]; and blurred vision
risk. In the present study, the incidence of these events was low,
and there was only one grade  3 event (grade 3 pleural effusion).
Although these AEs appear to be associated with trebananib
treatment, reasons for their onset remain unknown. Overall,
toxicity was manageable, and the incidence of AEs of any grade, AEs
grade 3, and serious AEs was similar across the treatment arms. If
further studies of trebananib are conducted in patients with breast
cancer, it will be crucial to more thoroughly characterize the pre-
disposition, onset, duration, impact on quality of life, and responsePlease cite this article in press as: Dieras V, et al., Trebananib (AMG 38
therapy for HER2-negative locally recurrent or metastatic breast cancer
10.1016/j.breast.2014.11.003to management of edema and other AEs associated with trebananib
treatment.
The estimation study design limited the assessment of the
treatment effect. However, the results were anticipated to inform
the design of future studies rather than demonstrate statistically
signiﬁcant improvements in outcomes between treatment arms
[27]. It should also be noted that while treatment in Arms A, B, and
Cwas blinded, treatment in ArmDwas open-label, whichmay have
inﬂuenced the investigators' assessments of efﬁcacy and toxicity
outcomes.Conclusion
In this phase 2 estimation study, there was no prolongation of
PFS with the addition of trebananib (3 or 10mg/kg) to bevacizumab
and paclitaxel at the doses tested. Toxicity of each of the regimens
was consistent with prior experience with each of the treatment
components. Data from the exposure-response analyses support
additional studies in locally recurrent or metastatic breast cancer of
trebananib plus paclitaxel at doses > 10 mg/kg.Funding
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AE adverse event
AUCss area under the concentrationeversusetime curve at
steady state
Cmax maximum observed concentration
Cmin minimum observed concentration
CT computed tomography
DOR duration of response
ECOG Eastern Cooperative Oncology Group
HR hazard ratio
MRI magnetic resonance imaging
NCI-CTCAE National Cancer Institute Common Terminology
Criteria for Adverse Events
ORR objective response rate
OS overall survival
PFS progression-free survival
Q2W every 2 weeks
QW once weekly
RECIST Response Evaluation Criteria in Solid Tumors
VEGF vascular endotheilial growth factor
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